What is Wedbush’s Forecast for Chimerix FY2028 Earnings?

Chimerix, Inc. (NASDAQ:CMRX) – Research analysts at Wedbush boosted their FY2028 earnings estimates for Chimerix in a research report issued to clients and investors on Tuesday, February 18th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn $0.58 per share for the year, up from their previous estimate of $0.47. Wedbush currently has a “Outperform” rating and a $7.00 target price on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.99) per share.

Separately, HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Chimerix in a research report on Tuesday.

Chimerix Trading Up 10.0 %

Shares of CMRX opened at $4.82 on Wednesday. Chimerix has a 52-week low of $0.75 and a 52-week high of $5.15. The firm has a 50-day moving average price of $3.64 and a 200 day moving average price of $1.88.

Institutional Investors Weigh In On Chimerix

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Stoneridge Investment Partners LLC grew its stake in shares of Chimerix by 22.5% in the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 8,134 shares during the last quarter. Bender Robert & Associates acquired a new stake in shares of Chimerix in the fourth quarter worth $37,000. Susquehanna Fundamental Investments LLC bought a new position in Chimerix in the fourth quarter worth $59,000. Jane Street Group LLC bought a new position in Chimerix in the fourth quarter worth $62,000. Finally, Diadema Partners LP bought a new position in Chimerix in the fourth quarter worth $101,000. Institutional investors and hedge funds own 45.42% of the company’s stock.

Insider Buying and Selling

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 20,760 shares of company stock worth $91,175. Insiders own 13.10% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.